Neogen Q3 FY26 slides: Food Safety growth offsets Animal Safety decline

Neogen reported Q3 FY26 revenue of $211.2M (vs. $204.49M consensus, a 3.28% surprise) and adjusted EPS $0.09 vs. $0.06 expected, but shares fell ~4.55% premarket after a prior-session 6.29% drop. Adjusted EBITDA was $48.2M (22.8% margin, +110 bps sequential); Food Safety core growth +4.0% while Animal Safety core contracted -8.7%, with supplier disruptions persisting. Management raised FY2026 revenue guidance to $857–$860M (adjusted EBITDA ~ $175M), highlighted a planned in-house Petrifilm manufacturing transition (Nov 2027), and expects a $160M genomics divestiture to help reduce net leverage (current gross debt $800M, cash $160M, net debt $640M).

Analysis

The market is pricing this name as execution-reflexive: near-term operational hiccups dominate headline reaction while optionality from a strategic reset is being discounted. Internalizing production shifts margin risk from variable COGS to capital and validation risk; that creates a convex payoff where successful operational commissioning lifts margins disproportionately but delays or failures compound cash conversion weakness.

Supply-chain frictions that selectively hit a product category create durable reallocation opportunities among distributors and OEM partners — winners will be those with localized capacity, dual-sourcing, or inventory intelligence that converts stockouts into permanent share gains. Conversely, contract manufacturers and upstream suppliers tied to the troubled SKUs face persistent pricing pressure and capacity idling that can compress their unit economics for multiple quarters.

Interest-rate and liquidity dynamics are the silent drivers: meaningful floating-rate exposure plus a near-term asset-sale dependency means equity returns are tightly coupled to the timing and use of divestiture proceeds. If proceeds are used to de-lever and invest in automation, equity rerating is probable; if proceeds are delayed or absorbed by transitional opex, downside can accelerate even if top-line stabilizes.

The actionable read: this is a classic execution-call trade with clustered catalysts (divestiture completion, manufacturing commissioning, supply normalization). Short-term volatility will be high, so the cleanest upside capture uses time-limited, capped-cost structures that lean into the company's ability to demonstrate sequential margin improvement over the next 6–12 months while limiting exposure to an operational setback.

Key Decisions for Investors

• Core tactical long (NEOG): Initiate a 1–1.5% portfolio position size with a 6–12 month horizon. Thesis: successful execution of manufacturing commissioning and allocation of divestiture proceeds should re-rate the multiple. Risk control: place a 20% stop-loss; target 30–40% upside under base-case execution (2:1+ reward/risk).
• Option-defined upside (NEOG): Buy a 9–12 month call spread to get leveraged exposure with limited downside — long nearer-dated LEAP call and sell a higher strike call to finance ~50–70% of premium. Time this 2–6 weeks ahead of the expected divestiture closing or an upcoming quarterly print that should show supply normalization. Reward: asymmetric upside if catalysts land; cost: limited to net premium.
• Hedge / pair (NEOG vs larger diagnostics peer e.g., IDXX): Go long NEOG and short ~0.5x of IDXX to isolate company-specific execution/capital-allocation upside while neutralizing broader sector moves. Horizon 6–12 months. Risk/reward: reduces market beta but retains event risk; expected payoff if company out-executes peers on margin recovery.
• Event-protection (NEOG puts): Buy 3–6 month protective puts sized to cover 50% of the equity notional to cap downside around key operational milestones. Use this if holding a larger exposure through the commissioning window; cost is insurance against a >25% gap down driven by missed validation or divestiture delays.